Global Ischemia Reperfusion Injury Market Research Report 2024

Publication ID:

PB502240450

Publication Date:

February 23, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Medical Devices [2]

Pharma & Healthcare [3]

Description:

Reperfusion injury or reperfusion insult, sometimes called ischemia-reperfusion injury (IRI) or reoxygenation injury, is the tissue damage caused when blood supply returns to tissue (re- + perfusion) after a period of ischemia or lack of oxygen (anoxia or hypoxia). The absence of oxygen and nutrients from blood during the ischemic period creates a condition in which the restoration of circulation results in inflammation and oxidative damage through the induction of oxidative stress rather than (or along with) restoration of normal function.
The global Ischemia Reperfusion Injury market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
Global Ischemia Reperfusion Injury key players include Angion Biomedica, Catalyst Biosciences, Ischemix Inc, etc.
North America is the largest market, with a share about 50%, followed by Europe, and Japan, both have a share over 20 percent.
In terms of product, Phase 2 is the largest segment, with a share about 40%. And in terms of application, the largest application is Kidney Injury, followed by Heart Injury, Intestine Injury, etc.
This report aims to provide a comprehensive presentation of the global market for Ischemia Reperfusion Injury, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Ischemia Reperfusion Injury.
Report Scope
The Ischemia Reperfusion Injury market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Ischemia Reperfusion Injury market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Ischemia Reperfusion Injury companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Angion Biomedica
Catalyst Biosciences
Ischemix Inc
Opsona Therapeutics
Pharming
TheraSource
Bolder Biotechnology
Corline Biomedical
Mifcortx
Balmes Transplantation
NovelMed Therapeutics
Hope Pharmaceuticals
Omeros Corp
Prothix
SBI Pharmaceuticals
Segment by Type
Phase 1
Phase 2
Preclinical
Segment by Application
Heart Injury
Kidney Injury
Intestine Injury
Other Injury
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Ischemia Reperfusion Injury companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Ischemia Reperfusion Injury Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Phase 1
1.2.3 Phase 2
1.2.4 Preclinical
1.3 Market by Application
1.3.1 Global Ischemia Reperfusion Injury Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Heart Injury
1.3.3 Kidney Injury
1.3.4 Intestine Injury
1.3.5 Other Injury
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Ischemia Reperfusion Injury Market Perspective (2019-2030)
2.2 Ischemia Reperfusion Injury Growth Trends by Region
2.2.1 Global Ischemia Reperfusion Injury Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Ischemia Reperfusion Injury Historic Market Size by Region (2019-2024)
2.2.3 Ischemia Reperfusion Injury Forecasted Market Size by Region (2025-2030)
2.3 Ischemia Reperfusion Injury Market Dynamics
2.3.1 Ischemia Reperfusion Injury Industry Trends
2.3.2 Ischemia Reperfusion Injury Market Drivers
2.3.3 Ischemia Reperfusion Injury Market Challenges
2.3.4 Ischemia Reperfusion Injury Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Ischemia Reperfusion Injury Players by Revenue
3.1.1 Global Top Ischemia Reperfusion Injury Players by Revenue (2019-2024)
3.1.2 Global Ischemia Reperfusion Injury Revenue Market Share by Players (2019-2024)
3.2 Global Ischemia Reperfusion Injury Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Ischemia Reperfusion Injury Revenue
3.4 Global Ischemia Reperfusion Injury Market Concentration Ratio
3.4.1 Global Ischemia Reperfusion Injury Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Ischemia Reperfusion Injury Revenue in 2023
3.5 Ischemia Reperfusion Injury Key Players Head office and Area Served
3.6 Key Players Ischemia Reperfusion Injury Product Solution and Service
3.7 Date of Enter into Ischemia Reperfusion Injury Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Ischemia Reperfusion Injury Breakdown Data by Type
4.1 Global Ischemia Reperfusion Injury Historic Market Size by Type (2019-2024)
4.2 Global Ischemia Reperfusion Injury Forecasted Market Size by Type (2025-2030)
5 Ischemia Reperfusion Injury Breakdown Data by Application
5.1 Global Ischemia Reperfusion Injury Historic Market Size by Application (2019-2024)
5.2 Global Ischemia Reperfusion Injury Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Ischemia Reperfusion Injury Market Size (2019-2030)
6.2 North America Ischemia Reperfusion Injury Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Ischemia Reperfusion Injury Market Size by Country (2019-2024)
6.4 North America Ischemia Reperfusion Injury Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Ischemia Reperfusion Injury Market Size (2019-2030)
7.2 Europe Ischemia Reperfusion Injury Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Ischemia Reperfusion Injury Market Size by Country (2019-2024)
7.4 Europe Ischemia Reperfusion Injury Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Ischemia Reperfusion Injury Market Size (2019-2030)
8.2 Asia-Pacific Ischemia Reperfusion Injury Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Ischemia Reperfusion Injury Market Size by Region (2019-2024)
8.4 Asia-Pacific Ischemia Reperfusion Injury Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Ischemia Reperfusion Injury Market Size (2019-2030)
9.2 Latin America Ischemia Reperfusion Injury Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Ischemia Reperfusion Injury Market Size by Country (2019-2024)
9.4 Latin America Ischemia Reperfusion Injury Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Ischemia Reperfusion Injury Market Size (2019-2030)
10.2 Middle East & Africa Ischemia Reperfusion Injury Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Ischemia Reperfusion Injury Market Size by Country (2019-2024)
10.4 Middle East & Africa Ischemia Reperfusion Injury Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Angion Biomedica
11.1.1 Angion Biomedica Company Detail
11.1.2 Angion Biomedica Business Overview
11.1.3 Angion Biomedica Ischemia Reperfusion Injury Introduction
11.1.4 Angion Biomedica Revenue in Ischemia Reperfusion Injury Business (2019-2024)
11.1.5 Angion Biomedica Recent Development
11.2 Catalyst Biosciences
11.2.1 Catalyst Biosciences Company Detail
11.2.2 Catalyst Biosciences Business Overview
11.2.3 Catalyst Biosciences Ischemia Reperfusion Injury Introduction
11.2.4 Catalyst Biosciences Revenue in Ischemia Reperfusion Injury Business (2019-2024)
11.2.5 Catalyst Biosciences Recent Development
11.3 Ischemix Inc
11.3.1 Ischemix Inc Company Detail
11.3.2 Ischemix Inc Business Overview
11.3.3 Ischemix Inc Ischemia Reperfusion Injury Introduction
11.3.4 Ischemix Inc Revenue in Ischemia Reperfusion Injury Business (2019-2024)
11.3.5 Ischemix Inc Recent Development
11.4 Opsona Therapeutics
11.4.1 Opsona Therapeutics Company Detail
11.4.2 Opsona Therapeutics Business Overview
11.4.3 Opsona Therapeutics Ischemia Reperfusion Injury Introduction
11.4.4 Opsona Therapeutics Revenue in Ischemia Reperfusion Injury Business (2019-2024)
11.4.5 Opsona Therapeutics Recent Development
11.5 Pharming
11.5.1 Pharming Company Detail
11.5.2 Pharming Business Overview
11.5.3 Pharming Ischemia Reperfusion Injury Introduction
11.5.4 Pharming Revenue in Ischemia Reperfusion Injury Business (2019-2024)
11.5.5 Pharming Recent Development
11.6 TheraSource
11.6.1 TheraSource Company Detail
11.6.2 TheraSource Business Overview
11.6.3 TheraSource Ischemia Reperfusion Injury Introduction
11.6.4 TheraSource Revenue in Ischemia Reperfusion Injury Business (2019-2024)
11.6.5 TheraSource Recent Development
11.7 Bolder Biotechnology
11.7.1 Bolder Biotechnology Company Detail
11.7.2 Bolder Biotechnology Business Overview
11.7.3 Bolder Biotechnology Ischemia Reperfusion Injury Introduction
11.7.4 Bolder Biotechnology Revenue in Ischemia Reperfusion Injury Business (2019-2024)
11.7.5 Bolder Biotechnology Recent Development
11.8 Corline Biomedical
11.8.1 Corline Biomedical Company Detail
11.8.2 Corline Biomedical Business Overview
11.8.3 Corline Biomedical Ischemia Reperfusion Injury Introduction
11.8.4 Corline Biomedical Revenue in Ischemia Reperfusion Injury Business (2019-2024)
11.8.5 Corline Biomedical Recent Development
11.9 Mifcortx
11.9.1 Mifcortx Company Detail
11.9.2 Mifcortx Business Overview
11.9.3 Mifcortx Ischemia Reperfusion Injury Introduction
11.9.4 Mifcortx Revenue in Ischemia Reperfusion Injury Business (2019-2024)
11.9.5 Mifcortx Recent Development
11.10 Balmes Transplantation
11.10.1 Balmes Transplantation Company Detail
11.10.2 Balmes Transplantation Business Overview
11.10.3 Balmes Transplantation Ischemia Reperfusion Injury Introduction
11.10.4 Balmes Transplantation Revenue in Ischemia Reperfusion Injury Business (2019-2024)
11.10.5 Balmes Transplantation Recent Development
11.11 NovelMed Therapeutics
11.11.1 NovelMed Therapeutics Company Detail
11.11.2 NovelMed Therapeutics Business Overview
11.11.3 NovelMed Therapeutics Ischemia Reperfusion Injury Introduction
11.11.4 NovelMed Therapeutics Revenue in Ischemia Reperfusion Injury Business (2019-2024)
11.11.5 NovelMed Therapeutics Recent Development
11.12 Hope Pharmaceuticals
11.12.1 Hope Pharmaceuticals Company Detail
11.12.2 Hope Pharmaceuticals Business Overview
11.12.3 Hope Pharmaceuticals Ischemia Reperfusion Injury Introduction
11.12.4 Hope Pharmaceuticals Revenue in Ischemia Reperfusion Injury Business (2019-2024)
11.12.5 Hope Pharmaceuticals Recent Development
11.13 Omeros Corp
11.13.1 Omeros Corp Company Detail
11.13.2 Omeros Corp Business Overview
11.13.3 Omeros Corp Ischemia Reperfusion Injury Introduction
11.13.4 Omeros Corp Revenue in Ischemia Reperfusion Injury Business (2019-2024)
11.13.5 Omeros Corp Recent Development
11.14 Prothix
11.14.1 Prothix Company Detail
11.14.2 Prothix Business Overview
11.14.3 Prothix Ischemia Reperfusion Injury Introduction
11.14.4 Prothix Revenue in Ischemia Reperfusion Injury Business (2019-2024)
11.14.5 Prothix Recent Development
11.15 SBI Pharmaceuticals
11.15.1 SBI Pharmaceuticals Company Detail
11.15.2 SBI Pharmaceuticals Business Overview
11.15.3 SBI Pharmaceuticals Ischemia Reperfusion Injury Introduction
11.15.4 SBI Pharmaceuticals Revenue in Ischemia Reperfusion Injury Business (2019-2024)
11.15.5 SBI Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Angion Biomedica
Catalyst Biosciences
Ischemix Inc
Opsona Therapeutics
Pharming
TheraSource
Bolder Biotechnology
Corline Biomedical
Mifcortx
Balmes Transplantation
NovelMed Therapeutics
Hope Pharmaceuticals
Omeros Corp
Prothix
SBI Pharmaceuticals

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂